MVA-BN-RSV

AXP000204.1 · Vaccine

Platform
MVA-BN
Targets
RSV F; RSV G (A and B); RSV N; RSV M2-1
Originator
Bavarian Nordic
Sponsor
Bavarian Nordic

Names

NameTypeSource
MVA-BN-RSVpreferred name, codecurator, press
MVA-RSV ambiguoussynonympaper
VANIR ambiguoussynonympress

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA-BN
Replication
non replicating
Modifications
five RSV antigen cassettes inserted into MVA-BN
Transgenes
RSV F (A long), RSV G (subtype A, A2), RSV G (subtype B), RSV N (A2), RSV M2-1 (A2)
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05238025MVA-BN-RSV Vaccine TrialTerminatedPhase 32022-04-192023-06-2920419Respiratory Syncytial Virus Infections
NCT04752644Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy AdultsCompletedPhase 22021-02-222021-06-1773RSV Infection
NCT02873286RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old AdultsCompletedPhase 22016-092018-12420Respiratory Syncytial Virus Infections
NCT02864628RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.WithdrawnPhase 12016-092017-10-270Respiratory Syncytial Virus Infections
NCT02419391Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV VaccineCompletedPhase 12015-082015-1263Respiratory Syncytial Virus Infections
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT01805921RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.CompletedPhase 12013-052015-0872Respiratory Syncytial Virus Infectionsname in intervention: MVA-RSV

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39461302A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.Vaccine2024cited by trial NCT05238025
PMID 37079393Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine.The Journal of infectious diseases2023cited by trial NCT04752644
PMID 32726422Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.The Journal of infectious diseases2021cited by trial NCT02873286
PMID 32057576Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial.Vaccine2020name in abstract: MVA-BN-RSV
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 26510727Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.BMJ open2015name in title: MVA-RSV

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40265347Analyzing Differences in Viral Dynamics Between Vaccinated and Unvaccinated RSV Patients.Epidemiologia (Basel, Switzerland)2025name in abstract: MVA-BN-RSV
PMID 36280532Development of mRNA vaccines against respiratory syncytial virus (RSV).Cytokine & growth factor reviews2022name in abstract: MVA-BN-RSV

Notes

MVA-BN encoding five RSV antigens: fusion protein F (RSV-A long), glycoprotein G of subtypes A (A2) and B, nucleoprotein N and transcription elongation factor M2-1 (A2). Single-dose phase 3 VANIR trial in >20,000 adults aged 60+ missed a co-primary endpoint (42.9% efficacy against disease with 3+ symptoms vs 59% with 2+), reported 22 July 2023; the programme was discontinued. Route not recorded here.

How to cite

MVA-BN-RSV (AXP000204.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000204.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.